九典制药：公司通过控股子公司诺纳医药收购了67个药品批文

Core Viewpoint - The company, through its subsidiary Nona Pharmaceutical, has acquired 67 drug approvals, including 8 exclusive products, which are expected to enhance its sales and stabilize performance [2] Group 1: Acquisition Details - The acquisition includes key products such as Daiwen Jiao Gao, which has unique advantages in medical insurance, helping to fill potential sales gaps from the company's participation in centralized procurement of Loxoprofen Sodium Gel [2] - The company aims to leverage its existing sales channels to achieve rapid growth in sales for the newly acquired products [2] Group 2: Strategic Implications - The introduction of differentiated categories such as traditional Chinese medicine external preparations will further enhance the company's treatment portfolio [2] - This strategic move is expected to stabilize the company's performance amidst potential challenges in the market [2]